JP4920675B2 - ニューロトリプシン阻害剤とその判定 - Google Patents

ニューロトリプシン阻害剤とその判定 Download PDF

Info

Publication number
JP4920675B2
JP4920675B2 JP2008503516A JP2008503516A JP4920675B2 JP 4920675 B2 JP4920675 B2 JP 4920675B2 JP 2008503516 A JP2008503516 A JP 2008503516A JP 2008503516 A JP2008503516 A JP 2008503516A JP 4920675 B2 JP4920675 B2 JP 4920675B2
Authority
JP
Japan
Prior art keywords
agrin
neurotrypsin
fragment
protein
cleavage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008503516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538178A (ja
JP2008538178A5 (https=
Inventor
ゾンダーエッガー，ペーター
ヘドヴァー，シュテファン
ボリガー，マルク・エフ
ドライアー，ビルギット
クンツ，ベアト
リュッシャー，ダニエル
ライフ，ライモント
ザーレス，スザンネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of JP2008538178A publication Critical patent/JP2008538178A/ja
Publication of JP2008538178A5 publication Critical patent/JP2008538178A5/ja
Application granted granted Critical
Publication of JP4920675B2 publication Critical patent/JP4920675B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008503516A 2005-03-30 2006-03-29 ニューロトリプシン阻害剤とその判定 Expired - Fee Related JP4920675B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102481 2005-03-30
EP05102481.8 2005-03-30
PCT/EP2006/061152 WO2006103261A2 (en) 2005-03-30 2006-03-29 Inhibitors of neurotrypsin and determination thereof

Publications (3)

Publication Number Publication Date
JP2008538178A JP2008538178A (ja) 2008-10-16
JP2008538178A5 JP2008538178A5 (https=) 2009-05-14
JP4920675B2 true JP4920675B2 (ja) 2012-04-18

Family

ID=34939082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503516A Expired - Fee Related JP4920675B2 (ja) 2005-03-30 2006-03-29 ニューロトリプシン阻害剤とその判定

Country Status (15)

Country Link
US (1) US7897364B2 (https=)
EP (1) EP1868989A2 (https=)
JP (1) JP4920675B2 (https=)
KR (1) KR20070116932A (https=)
CN (1) CN101193858B (https=)
AU (1) AU2006228150B2 (https=)
BR (1) BRPI0609654A2 (https=)
CA (1) CA2600791A1 (https=)
IL (1) IL186120A (https=)
MX (1) MX2007011961A (https=)
NO (1) NO20075461L (https=)
NZ (1) NZ562796A (https=)
RU (1) RU2424228C2 (https=)
WO (1) WO2006103261A2 (https=)
ZA (1) ZA200707359B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074813A2 (en) * 2006-12-21 2008-06-26 Neurotune Ag Optiogenin for the treatment of neural diseases
PL1990420T3 (pl) * 2007-05-10 2011-01-31 Neurotune Ag Sposób wykrywania aktywności neurotrypsyny in vivo, zastosowanie tego sposobu i zastosowanie C-końcowego fragmentu agryny 22 kDa jako biomarkera w diagnozowaniu i monitorowaniu zaburzeń związanych z neurotrypsyną
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
EP2635559A2 (en) 2010-11-01 2013-09-11 Neurotune AG Neurotrypsin inhibitors
WO2012059443A2 (en) 2010-11-01 2012-05-10 Neurotune Ag Novel neurotrypsin inhibitors
EP2631657A1 (en) * 2012-02-25 2013-08-28 Neurotune AG Immunoassay for the detection of the 22kDa C-terminal fragment (CAF) of agrin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH692507A5 (de) * 1997-04-26 2002-07-15 Peter Prof Dr Sonderegger Neurotrypsin als aktive Verbindung in einem Medikament.
DE19919634C2 (de) * 1999-04-30 2001-06-07 Aventis Pharma Gmbh Test zur Bestimmung der Integrität komplexer Phospholipid/Lipid-Strukturen mit Hilfe synthetischer fluoreszenz-markierter Acylglyceride und dessen Anwendung zur Bestimmung der Aktivität von Lipasen
DE10247478A1 (de) * 2002-10-11 2004-06-24 Bioagency Ag Verfahren zur Bestimmung der enzymatischen Aktivität von Proteinen

Also Published As

Publication number Publication date
EP1868989A2 (en) 2007-12-26
KR20070116932A (ko) 2007-12-11
WO2006103261A9 (en) 2010-05-27
CN101193858A (zh) 2008-06-04
CA2600791A1 (en) 2006-10-05
JP2008538178A (ja) 2008-10-16
RU2424228C2 (ru) 2011-07-20
WO2006103261A3 (en) 2007-02-22
IL186120A (en) 2012-08-30
AU2006228150A1 (en) 2006-10-05
RU2007139754A (ru) 2009-05-10
WO2006103261A2 (en) 2006-10-05
AU2006228150B2 (en) 2011-09-29
US7897364B2 (en) 2011-03-01
US20090170950A1 (en) 2009-07-02
ZA200707359B (en) 2009-08-26
IL186120A0 (en) 2008-01-20
NO20075461L (no) 2007-11-20
BRPI0609654A2 (pt) 2010-04-20
MX2007011961A (es) 2008-03-14
CN101193858B (zh) 2012-01-04
NZ562796A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
AU2002213138B2 (en) Novel serine protease genes related to DPPIV
JP4358159B2 (ja) 血管形成及び心臓血管新生の促進又は阻害
JPH022372A (ja) 活性化されたヒトプロテインｃの直接発現のためのベクターおよび化合物
IL186120A (en) Method for determining whether a test compound is an inhibitor of neurotrypsin
US20100221254A1 (en) Methods and Compositions for PDGF-C Activation and Inhibition
JP2003511028A (ja) 新規ポリペプチド、その核酸および新脈管形成および血管新生におけるその使用のための方法
EP1314779B1 (en) Airway-specific trypsin-like enzymes and method of using the same
KR20070000501A (ko) 절단형 ｄａｎｃｅ, ｄａｎｃｅ 복합체, 및 이들을사용하는 방법
JP2007510425A (ja) ＢＡＣＥ４５５、ヒトβ−セクレターゼの選択的スプライシング変異体
JP2002532065A (ja) 哺乳動物サブチリシン／ケキシンアイソエンザイムｓｋｉ−１：独特の切断特異性を有するプロタンパク質コンバーターゼ
HK1119156A (en) Inhibitors of neurotrypsin and determination thereof
JPWO2004019983A1 (ja) 糖代謝関連遺伝子の転写因子の分解方法、分解阻害方法および分解阻害剤
US20040038369A1 (en) Airway-specific trypsin-like enzymes and method of using the same
AU2006228068B2 (en) Novel serine protease genes related to DPPIV
WO2026006884A1 (en) Modulators of fxii-upar
JP2009538124A (ja) スクリーニング方法
NZ542643A (en) Serine protease genes related to Dipeptidyl peptidase IV

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120124

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120201

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150210

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees